T cell receptor specific for diphtheria toxoid-derived peptides presented on MHC class II (DT-specific TCR)

T cell receptors (TCRs) specific for diphtheria toxoid-derived peptides presented on MHC class II are specialized protein complexes found on the surface of CD4+ T lymphocytes. These receptors play a pivotal role in the adaptive immune response by recognizing processed fragments of the diphtheria toxoid (DT) antigen when they are displayed by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells (PMID: 10608765). This recognition event is the primary signal for T cell activation, leading to the secretion of cytokines such as IL-4 and IFN-gamma, which are essential for stimulating B cells to produce neutralizing antibodies against the diphtheria toxin (PMID: 3871941). In the context of clinical immunology, these TCRs are the focus of studies regarding vaccine-induced long-term immunity and the "carrier effect" in conjugate vaccines, where DT-specific T cell help is leveraged to enhance responses to polysaccharide antigens (PMID: 21930769). While these TCRs are not typically targeted by small molecule inhibitors, they are critical targets for monitoring vaccine efficacy and are being explored in the development of TCR-based diagnostics and immunotherapies (PMID: 12133961). Safety considerations regarding these receptors primarily involve potential cross-reactivity with self-peptides, which could theoretically lead to autoimmune phenomena, although such events are rare in the context of standard vaccination. Furthermore, the diversity of the TCR repertoire specific to DT can serve as a biomarker for the robustness of an individual's immune memory. Understanding the structural basis of how these TCRs bind to DT-MHC II complexes aids in the design of more effective vaccines.

Other names

Diphtheria toxoid-specific T-cell receptorDT-specific TCRMHC II-restricted DT-specific TCRCD4+ T-cell receptor for diphtheria toxoid

Recognition of processed diphtheria toxoid peptides presented by MHC class II molecules, leading to CD4+ T cell activation and subsequent B cell help for antibody production.